![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/prof._josep_samitier_director_institute_for_bioengineering_of_catalonia.png?itok=pTHG1ZxP&c=e3a081f055d35d3c51010b7204a9a5da)
Josep Samitier
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/dr._philip_hewitt_global_head_of_early_non_clinical_safety_liver_and_kidney_merck_kgaa.jpg?itok=SMoSF2jh&c=f9919c431995eaa8a3ba663d9959ce4f)
Philip Hewitt
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/professor_magnus_ingelman-sundberg_karolinska_institutet.jpg?itok=C2C9-LGK&c=09dffa107af65edadc8fce6a4a60cbd8)
Magnus Ingelman-Sundberg
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/professor_paul_gatenholm_3d_bioprinting_center_department_of_chemistry_and_chemical_engineering_chalmers_university_of_technology.jpg?itok=FwPPyP4x&c=89aa6f8ac58b85b85e9640aaf1d008ea)
Professor Paul Gatenholm
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/dr._robert_vries_managing_director_the_hub_foundation_for_organoid_technology.jpg?itok=blvphJXC&c=13c3a19ad284731c466c4ed2811523c8)
Robert Vries
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/prof._tommy_andersson_principal_scientist_rd_innovative_medicines_astrazeneca.png?itok=-TwEolbM&c=c0d532d6dc21517eecf46cc5973c63a2)
Tommy Andersson
Heinz-Ruffner
Gabor Forgacs
![](https://kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/david_h._donabedian_ph.d.jpg?itok=R_nWkT3p&c=43dca56bbaec5f289874ebd83d47161f)
David H. Donabedian
David H. Donabedian, Ph.D., will serve as Chief Executive Officer of Axial and will also serve on its Board. Dr. Donabedian is an accomplished business development and strategy executive with extensive leadership experience. Dr. Donabedian has a track record of building companies, most recently as a Venture Partner at Longwood Fund.
Prior to joining Longwood, Dr. Donabedian has held various leadership roles at biopharmaceutical companies including AbbVie and GSK. At AbbVie, Dr. Donabedian served as Vice President & Global Head of Ventures and Early Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President Global New Deal Strategy and Development at GlaxoSmithKline, and Senior Manager at Accenture’s Strategic Services Consulting Group.
He holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Alcyone Life Sciences, a privately held CNS company which he co-founded.